Several possible studies
Story checked
GLP-1 drugs can ‘reverse biologic aging’ by two to three years (opens in a new tab)
nypost.com · 2026-10-11
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
GLP-1 drugs can ‘reverse biologic aging’ by two to three years
nypost.com · 2026-10-11
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 6Not checkedGLP-1 weight-loss drugs could slow biological aging and may even 'reverse biologic aging' by two to three years.View evidenceHide evidence
As statedtwo to three years
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 6Not checkedPharmaceutical companies and makers of GLP-1 medications say the blockbuster drugs can slow biological aging, and the article frames this as evidence they might be a true longevity treatment.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 6Not checkedAt the Aging Research & Drug Discovery conference, Novo Nordisk and Eli Lilly shared findings from several trials on the effects of semaglutide and tirzepatide on aging.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 6Not checkedNovo Nordisk said blood draws from 10,052 people, half on semaglutide and half on placebo, were analyzed with proteomic clocks, and Eli Lilly reported a smaller tirzepatide study using epigenetic clocks.View evidenceHide evidence
As stated10,052 people
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 6Not checkedThe article says the drugs slowed aging by as much as four years on a heart-protein clock, though the effect varied widely depending on the clock and organ tested.View evidenceHide evidence
As statedas much as four years
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 6Not checkedThe article cautions that it is unclear whether the anti-aging effects would extend to healthy people, because the reported studies involved patients with obesity or type 2 diabetes.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Crossref, Europe PMC · 15 candidate papers
Epigenetic Aging and Treatment Response to Semaglutide in the SLIM LIVER Study.
Research Square · 2025 · PubMed
Latest Topic for Clinical Effects of Tirzepatide as Dual GIP/GLP-1 Receptor Agonist
Journal of Medical and Clinical Studies · 2022 · Crossref
A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.
CPT: Pharmacometrics & Systems Pharmacology · 2026 · PubMed, Europe PMC
Review for "A Phase 3 Randomized Clinical Trial using Once‐Weekly GLP ‐1 Receptor Agonist in Adolescents and Young Adults with Hypothalamic Obesity"
2020 · Crossref
Beyond disease treatment and prevention: From geroscience and molecular hallmarks to gerotherapeutics and precision geromedicine.
Journal of the Chinese Medical Association : JCMA · 2026 · PubMed, Europe PMC
And 10 more candidates considered.